LianBio enters pact with Bristol Myers for Mavacamten in China, Asian markets

LianBio (LIAN) announced that the company has entered into an agreement with Bristol Myers Squibb (BMY), whereby BMS has obtained LianBio’s exclusive rights to develop and commercialize mavacamten in Mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand, in conjunction with termination of the exclusive license agreement LianBio previously entered into with MyoKardia, Inc., now a wholly owned subsidiary of BMS, in August 2020 to acquire such rights. Under the terms of the agreement, LianBio will receive a one-time payment of $350M. In addition, LianBio will be released from payment obligations of up to $127.5M in remaining milestone payments under the MyoKardia license agreement. In April 2023, the China National Medical Products Administration accepted with Priority Review a NDA for mavacamten for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy. LianBio received approval in Macau and Singapore for mavacamten for the treatment of adults with symptomatic oHCM in 2023.